Clinical utility of ADHD symptom thresholds to assess normalization of executive function with lisdexamfetamine dimesylate treatment in adults

Current Medical Research and Opinion

Volumn 27, Issue SUPPL. 2, 2011, Pages 23-33

  Brown, Thomas E ^a   Brams, Matthew ^b   Gasior, Maria ^c   Adeyi, Ben ^c   Babcock, Thomas ^c   Dirks, Bryan ^c   Scheckner, Brian ^c   Wigal, Timothy ^d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Bayou City Research   (United States)

^c SHIRE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ADHD; BADDS; Executive function; Lisdexamfetamine dimesylate; Receiver operating characteristics; ROC

Indexed keywords

LISDEXAMFETAMINE;

ACCURACY; ADHD RATING SCALE IV; ADULT; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; BRONCHITIS; BROWN ADD SCALE FOR ADULTS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MENTAL FUNCTION; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; QUALITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SYMPTOM; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VALIDATION PROCESS; XEROSTOMIA;

ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DEXTROAMPHETAMINE; DOUBLE-BLIND METHOD; EXECUTIVE FUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; ROC CURVE; YOUNG ADULT;

EID: 80053601887     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.605441     Document Type: Article

References (47)

1. American Psychiatric Association. Attention-deficit and disruptive behavior disorders. In: Diagnostic and Statistical Manual of Mental Disorders DSMIV-TR, 4th Edn, Text Revision. Washington, DC: American Psychiatric Association, 2000:85-93
2. Stefanatos GA, Baron IS. Attention-deficit/hyperactivity disorder: a neuropsychological perspective towards DSM-V. Neuropsychol Rev 2007;21:5-38 (Pubitemid 46355009)
3. Brown TE. DSM-IV: ADHD and executive function impairments. Adv Stud Med 2002;2:910-14
4. Faraone SV, Biederman J, Spencer T, et al. Diagnosing adult attention deficit hyperactivity disorder: are late onset and subthreshold diagnoses valid? Am J Psychiatry 2006;163:1720-9 (Pubitemid 44522480)
5. Spencer TJ, Biederman J, Mick E. Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology. J Pediatr Psychol 2007;32:631-42
6. McGough JJ, Barkley RA. Diagnostic controversies in adult attention deficit hyperactivity disorder. Am J Psychiatry 2004;161:1948-56 (Pubitemid 39441393)
7. American Psychiatric Association. Attention Deficit/Hyperactivity Disorder. 314.0x. Summary of changes under consideration for ADHD. Available at: http://www.dsm5.org/ProposedRevisions/Pages/proposedrevision.aspx?rid383 [Last accessed 17 March 2010]
8. DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation. New York, NY: Guilford Press, 1998
9. Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 2000;157:816-18 (Pubitemid 30249663)
10. Steele M, Jensen PS, Quinn DMP. Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther 2006;28:1892-908 (Pubitemid 46038524)
11. Brown TE. Executive functions and attention deficit hyperactivity disorder: implications of two conflicting views. Int J Disability Develop Educ 2006;53:35-46 (Pubitemid 43328825)
12. Castellanos FX, Sonuga-Barke EJ, Milham MP, et al. Characterizing cognition in ADHD: beyond executive dysfunction. Trends Cogn Sci 2006;10:117-23
13. Barkley RA. Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull 1997;121:65-94 (Pubitemid 127705285)
14. Hervey AS, Epstein JN, Curry JF. Neuropsychology of adults with attentiondeficit/hyperactivity disorder: a meta-analytic review. Neuropsychology 2004;18:485-503 (Pubitemid 38944385)
15. Barkley RA, Murphy KR. Impairment in occupational functioning and adult ADHD: the predictive utility of executive function (EF) ratings versus EF tests. Arch Clin Neuropsychol 2010;25:157-73
16. Shallice T, Burgess PW. Deficits in strategy application following frontal lobe damage in man. Brain 1991;114:727-41
17. Alderman N, Burgess PW, Knight C, et al. Ecological validity of a simplified version of the multiple errands shopping test. J Int Neuropsychol Soc 2003; 9:31-44 (Pubitemid 36150136)
18. Biederman J, Petty CR, Fried R, et al. Stability of executive function deficits into young adult years: a prospective longitudinal follow-up study of grown up males with ADHD. Acta Psychiatr Scand 2007;116:129-36 (Pubitemid 47076271)
19. Boonstra AM, Kooij JJ, Oosterlaan J, et al. To act or not to act, that's the problem: primarily inhibition difficulties in adult ADHD. Neuropsychology 2010;24:209-21
20. Brown TE. Brown Attention-Deficit Hyperactivity Disorder Scales for Adolescents and Adults. San Antonio, TX: The Psychological Corporation, 1996
21. Vyvanse [package insert]. Wayne, PA, USA: Shire US Inc., 2010
22. Wigal T, Brams M, Gasior M, et al. on behalf of the 316 Study Group. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder: novel findings using the adult workplace environment design. Behav Brain Funct 2010;6:34
23. Lasko TA, Bhagwat JG, Zou KH, et al. The use of receiver operating characteristic curves in biomedical informatics. J Biomed Inform 2005;38:404-15 (Pubitemid 41405811)
24. Faries DE, Yalcin I, Harder D, et al. Validation of the ADHD Rating Scale as a clinician administered and scored instrument. J Atten Disord 2001;5:107-15 (Pubitemid 33794656)
25. Kaufman AS, Kaufman NL. KBIT-2: Kaufman Brief Intelligence Test, 2nd Upper Saddle River, NJ: Pearson Education, Inc., 2004
26. Swanson J, Wigal S, Greenhill L, et al. Objective and subjective measures of the pharmacodynamic effects of Adderall in the treatment of children with ADHD in a controlled laboratory classroom setting. Psychopharmacol Bull 1998;34:55-60 (Pubitemid 28176302)
27. Brown T. Attention Deficit Disorder: The Unfocused Mind in Children and Adults. New Haven, CT: Yale University Press, 2005
28. Swanson JM, Kraemer HC, Hinshaw SP, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 2001;40:168-79 (Pubitemid 32111020)
29. Brown TE. Brown Attention-Deficit Disorder Scales for Children and Adolescents. San Antonio, TX: The Psychological Corp., 2001:1-149
30. Adler LA, Goodman DW, Kollins SH, et al. on behalf of the 303 Study Group. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2008;69:1364-73
31. Weisler R, Young J, Mattingly G, et al. on behalf of the 304 Study Group. Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. CNS Spectr 2009;14:573-85
32. Biederman J, Mick E, Surman C, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2006;59:829-35
33. Medori R, Ramos-Quiroga JA, Casas M, et al. A randomized, placebocontrolled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2008;63:981-9
34. Reimherr FW, Williams ED, Strong RE, et al. A double-blind, placebocontrolled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry 2007;68:93-101 (Pubitemid 46220130)
35. Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr 2006;11:625-39 (Pubitemid 44253518)
36. Biederman J, Spencer TJ, Wilens TE, et al. on behalf of the SLI 381.304 Study Group. Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr 2005;10:16-25 (Pubitemid 43010494)
37. Spencer TJ, Adler LA, McGough JJ, et al. the Adult ADHD Research Group. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2007; 61:1380-7 (Pubitemid 46855767)
38. Willcutt EG, Doyle AE, Nigg JT, et al. Validity of the executive function theory of attention-deficit/hyperactivity disorder: A meta-analytic review. Biol Psychiatry 2005;57:1336-46 (Pubitemid 40798553)
39. Loo SK, Humphrey LA, Tapio T, et al. Executive functioning among Finnish adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46:1594-604 (Pubitemid 350146524)
40. Nigg JT, Willcutt EG, Doyle AE, et al. Causal heterogeneity in attention-deficit/hyperactivity disorder: do we need neuropsychologically impaired subtypes? Biol Psychiatry 2005;57:1224-30 (Pubitemid 40798539)
41. Biederman J, Petty C, Fried R, et al. Impact of psychometrically defined deficits of executive functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 2006;163:1730-8 (Pubitemid 44522481)
42. Fallu A, Richard C, Prinzo R, et al. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder. Curr Med Res Opin 2006;22:2557-66 (Pubitemid 46048371)
43. Biederman J, Seidman LJ, Petty CR, et al. Effects of stimulant medication on neuropsychological functioning in young adults with attention-deficit/ hyperactivity disorder. J Clin Psychiatry 2008;69:1150-6 (Pubitemid 352031599)
44. Brown TE, Brams M, Gao J, et al. Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults. Postgrad Med 2010; 122:7-17
45. Spencer TJ, Adler LA, Weisler RH, et al. Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study. J Clin Psychiatry 2008;69:1437-48
46. Brown TE, Holdnack J, Saylor K, et al. Effect of atomoxetine on executive function impairments in adults with ADHD. J Atten Disord 2011;15:130-8
47. Findling RL, Adeyi B, Chen G, et al. Clinical response and symptomatic remission in children treated with lisdexamfetamine dimesylate for attention-deficit/hyperactivity disorder. CNS Spectrums 2010;15:559-68